Vincamine Description
Vincamine is an indole alkaloid found in the leaves of V. minor and C. roseus that is used as a peripheral vasodilator to increase blood flow to the brain. Vincamine contracts excised human cerebrovascular smooth muscle in vitro with an EC50 value of 30 μM and has been explored as a pharmacotherapy to treat cerebral metabolic and vascular diseases. Stanford Advanced Materials (SAM) provides customers with high-quality Vincamine at a competitive price.
Vincamine is a monoterpenoid indole alkaloid obtained from the leaves of Vinca minor with a vasodilatory property.
Vincamine Specifications
| Product Name |
Vincamine |
| CAS Registry Number |
1617-90-9 |
| Molecular Formula |
C21H26N2O3 |
| Molecular Weight |
354.4 g/mol |
| Purity |
>99% |
| Appearance |
White powder |
| Package |
1kg-25kg |
| Shelf life |
2 years |
| Functions |
Treatment of arteriosclerosis, cerebral infarction |
Vincamine Applications
Vincamine can be used in the following fields:
- Treatment of ischemic cerebrovascular disease
- Laboratory research
FAQs about Vincamine
Q: What are the benefits of vincamine?
A: Vincamine is used to improve brain function, particularly in conditions like age-related cognitive decline, memory loss, and cerebrovascular insufficiency. It may enhance blood flow and oxygen supply to the brain.
Q: Is vincamine safe?
A: Vincamine is generally safe when used as prescribed, but it may cause side effects like nausea, dizziness, or gastrointestinal discomfort. It should be used under medical supervision, especially for individuals with heart conditions or low blood pressure.
Reference:
- Young, A.R., Bouloy, M., Boussard, J.F., et al. Direct vascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels. Journal of Cerebral Blood Flow and Metabolism 1(1), 117-128 (1981).
- Lim, C.C., and James, I.M. The effect of an acute infusion of vincamine and ethyl apovincaminate on cerebral blood flow in healthy volunteers. British Journal of Clinical Pharmacology 9(1), 100-101 (1980).
- Nowicki, J.P., MacKenzie, E.T., and Spinnewyn, B. Effects of agents used in the pharmacotherapy of cerebrovascular disease on the oxygen consumption of isolated cerebral mitochondria. Journal of Cerebral Blood Flow and Metabolism 2(1), 33-40 (1982).
